Biopharmaceutical company Propanc Biopharma Inc (OTC:PPCBD) on Monday provided an update on the preparation of its anti-cancer lead product candidate PRP for clinical trial application submission as well as its reverse stock split.
The company stated that it intends to file its first clinical trial application of PRP in the second half of 2019 as well as launch its First-In-Human (FIH) study in advanced cancer patients for PRP during the first half of 2020. Approximately 80% of cancers are from solid tumors and metastasis is the main cause of patient death.
According to the company, PRP targets cancer stem cells resistant to standard treatments, that remain dormant for long periods then migrate to other organs, triggering explosive tumor growth and causing patient relapse. PRP is the mixture of two proenzymes (trypsinogen and chymotrypsinogen) from bovine pancreas. A synergistic ratio of these proenzymes inhibits growth of most tumor cells. Efficacy has been shown in pancreatic, kidney, breast, brain, prostate, lung, liver, uterine, and skin cancers .
At the opening of business on 24 June 2019, the company had completed its one for 500 reverse stock split of its common stock and the shares are now trading on the OTCQB on a post-split adjusted price. The trading symbol has temporarily changed to PPCBD and the trading symbol will revert to its original symbol PPCB.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review